Aclaris Therapeutics, Inc. (ACRS)
5.145
-0.24
(-4.37%)
USD |
NASDAQ |
Sep 25, 16:00
5.145
0.00 (0.00%)
After-Hours: 19:59
Aclaris Therapeutics Research and Development Expense (Annual) : 52.64M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 52.64M |
| December 31, 2024 | 32.09M |
| December 31, 2023 | 98.38M |
| December 31, 2022 | 77.81M |
| December 31, 2021 | 43.81M |
| December 31, 2020 | 29.34M |
| December 31, 2019 | 63.78M |
| Date | Value |
|---|---|
| December 31, 2018 | 59.57M |
| December 31, 2017 | 39.79M |
| December 31, 2016 | 29.74M |
| December 31, 2015 | 14.96M |
| December 31, 2014 | 6.507M |
| December 31, 2013 | 3.488M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Corcept Therapeutics, Inc. | 254.91M |
| Nektar Therapeutics | 117.07M |
| Xeris Biopharma Holdings, Inc. | 31.16M |
| Alumis, Inc. | 377.10M |
| ANI Pharmaceuticals, Inc. | 51.66M |